ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
June 05 2023 - 2:00AM
ERYTECH announces that Akkadian has initiated proceedings to
postpone the vote on the merger with Pherecydes
ERYTECH announces that
Akkadian has initiated proceedings to postpone the
vote on the merger with
Pherecydes
Cambridge, MA (U.S.) and Lyon
(France), June 5,
2023 –
ERYTECH Pharma (Nasdaq &
Euronext: a clinical-stage
biopharmaceutical company developing innovative therapies by
encapsulating therapeutic drug substances inside red blood cells,
today announced that Akkadian
Partners has initiated legal proceedings to obtain the postponement
of the vote on the merger with Pherecydes
at the Annual General Meeting on June 23.
Akkadian's legal action against ERYTECH aims to
obtain the adjournment of the vote on certain resolutions at the
Annual General Meeting scheduled for June 23, 2023, so that ERYTECH
shareholders will not be able to vote on the merger with
Pherecydes.
Akkadian is also requesting the appointment of a
legal expert to review the terms of the merger.
Akkadian Partners' legal action is part of their
campaign to destabilize ERYTECH. To the best of ERYTECH's
knowledge, Akkadian held 1,850,000 ERYTECH shares on May 24, 2023,
representing around 5% of the company's share capital.
ERYTECH intends to obtain the dismissal of this
legal action, which it considers unfounded, and thus enable its
shareholders to vote on the merger with Pherecydes on June 23.
About ERYTECH
ERYTECH is a biopharmaceutical company
developing innovative red blood cell-based therapeutics for severe
forms of cancer and orphan diseases.
On February 15 2023, ERYTECH announced its
intended strategic combination with PHERECYDES to create a global
player in extended phage. More detail can be found in the press
release.
ERYTECH is listed on the Nasdaq Capital Market
in the United States (ticker: ERYP) and on the Euronext regulated
market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is
part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid &
Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech
indexes.
For more information, please visit
www.erytech.com
CONTACTS
ERYTECH
Eric SoyerCFO & COO |
NewCapMathilde Bohin / Louis-Victor
DelouvrierInvestor relationsNicolas
MerigeauMedia relations |
+33 4 78 74 44
38investors@erytech.com |
+33 1 44 71 94 94
erytech@newcap.eu |
- 20230605_ERYTECH_PR_référé_EN_vf
Phaxiam Therapeutics (LSE:0QSS)
Historical Stock Chart
From Apr 2024 to May 2024
Phaxiam Therapeutics (LSE:0QSS)
Historical Stock Chart
From May 2023 to May 2024